Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...